BMS-986435 for Liver Disease

This trial tests a new treatment called BMS-986435 to evaluate its movement through the body and its safety for individuals with liver disease. The study will include participants with mild and moderate liver problems, as well as those with normal liver function for comparison. It aims to better understand how the medication affects individuals with varying liver function levels. Candidates may qualify if they have liver issues but no serious heart conditions, and maintain a healthy weight and kidney function. As a Phase 1 trial, participants will be among the first to receive this new treatment, aiding researchers in understanding its effects in people.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Studies of BMS-986435 have suggested that it is safe in controlled settings. This treatment is being tested for individuals with heart failure and liver conditions. So far, patients have tolerated it well, and no major side effects have been reported. However, liver problems can affect drug efficacy and safety, making it crucial to monitor liver function when testing new treatments like BMS-986435. Participants in a clinical trial will have their side effects closely monitored by researchers to ensure safety.¹²³⁴⁵

BMS-986435 is unique because it targets liver disease with a novel mechanism of action, potentially offering better outcomes for patients with varying degrees of hepatic impairment. Current treatments often focus on managing symptoms rather than addressing underlying causes. Researchers are excited about BMS-986435 because it could improve liver function more directly, offering a targeted approach for both mild and moderate hepatic impairment. This specificity in targeting liver function could lead to more effective and personalized treatment options compared to standard therapies.

This trial will evaluate BMS-986435 for liver disease across different levels of hepatic function. Research suggests that BMS-986435 could aid liver disease by targeting liver function. The treatment aims to improve liver health by focusing on specific liver processes. Although direct evidence on BMS-986435's effectiveness is limited, similar drugs have shown promise in treating liver conditions like non-alcoholic steatohepatitis (NASH), a type of fatty liver disease. This suggests that BMS-986435 might work similarly. More studies are needed to confirm its benefits, but the approach appears promising based on its intended mechanism in the body.⁶⁷⁸⁹¹⁰